Search global stocks & ETFs...Ctrl K
Learn Mode
BIIB
Stock Profile
07-29
Recommended Metric
Score Card
Explore Scores Tab
3.34
Average
Valuation Score
Key Score
3.00
Average
Management
3.00
Average
Growth
1.00
Very Bad
Profitability
4.00
Good
Fin. Health
4.00
Good
Dividends
--
--
Analyst
1.00
Very Bad
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
1-year price targets, ending May 11, 2027
Current
$209.74
Baseline
High
$288.75
▲
37.67%
Avg
$222.47
▲
6.07%
Low
$151.50
▼
-27.77%
Analyst Ratings based on 44 Analysts
Strong Buy
920%
Buy
1841%
Hold
1636%
Sell
102%
Strong Sell
000%
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,500 full-time employees. The firm is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. The company operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. The company also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).Read More